The central player, tumor necrosis factor alpha-induced protein 8, or TIPE, has attracted growing attention in cancer research because of its role in regulating inflammatory and immune signaling pathways. The research team began by examining colorectal cancer tissue samples and found that TIPE expression was elevated in tumor tissue. More strikingly, the abundance of TIPE correlated positively with the levels of characteristic markers of M2 macrophages, including CD206, CD163, and the anti-inflammatory cytokine interleukin-10. This correlation mattered because macrophages are not a uniform population. In simplified terms, M1 macrophages tend to mount inflammatory attacks against tumor cells, while M2 macrophages promote tissue repair, wound healing, and, unfortunately for patients, tumor progression and immunosuppression. A tumor rich in M2 macrophages is a tumor that has effectively recruited the body’s own repair machinery to its cause.

To determine whether TIPE was merely a bystander or an active driver of this macrophage shift, the investigators combined bioinformatic analysis with laboratory experiments conducted both in cell culture and in living models. The results pointed clearly to a functional role. When TIPE levels rose, macrophages were pushed toward the M2 phenotype, adopting the marker profile and cytokine output that define tumor-promoting immune cells. Crucially, the team identified the intermediary in this process: decoy receptor 3, or DcR3, a secreted protein that TIPE upregulates. DcR3 earned its name because it acts as a molecular decoy, binding to signaling molecules that would otherwise alert the immune system and thereby dampening immune responses. The new work shows that in colorectal cancer, DcR3 is not just a passive suppressor of immune alerts but an active instructor of macrophage identity.

The mechanistic heart of the study lies in what happens after DcR3 is released into the tumor microenvironment. Using a series of binding and signaling experiments, the researchers demonstrated that DcR3 physically attaches to heparan sulfate proteoglycan 2, or HSPG2, a component of the extracellular matrix that surrounds cells. This interaction depends on heparan sulfate, a sugar chain modification carried by HSPG2. In other words, the sugar-decorated matrix protein serves as the docking station that allows DcR3 to engage its partner and transmit a signal into the macrophage. This level of molecular detail matters because it identifies specific points of contact that could, in principle, be targeted with drugs designed to interrupt the interaction.

Once DcR3 docks onto HSPG2, the signal that flows into the macrophage travels through one of the cell’s most well-known growth and survival pathways: the AKT signaling cascade, specifically through the protein kinase B alpha 1 isoform, AKT1. AKT1 activation is a classic pro-growth signal in many cell types, and the study shows that in macrophages it serves as the switch that drives M2 polarization directly. When the pathway is engaged, macrophages commit to the tumor-supportive M2 state, producing the cytokines and surface markers that suppress anti-tumor immunity. This finding ties together a long-recognized association between PI3K-AKT signaling and macrophage polarization with a specific upstream trigger that tumors can deploy at will.

But the story does not end with polarization alone. The researchers found that AKT1 activation also changes where macrophages go. Activated macrophages upregulate CXCL8, a chemokine, a type of signaling molecule that attracts cells bearing matching receptors. Through CXCL8, macrophages enhance their own chemotaxis and recruitment toward colorectal cancer cells, creating a self-reinforcing loop. Tumor-associated macrophages drawn into the tumor core become more numerous, more firmly embedded in the malignant tissue, and more committed to the M2 program. The tumor thus does not merely convert the immune cells that happen to be nearby; it actively broadcasts a signal that summons more macrophages and then converts them upon arrival. This dual effect, polarization plus recruitment, helps explain why high TIPE expression is associated with an immunosuppressive tumor microenvironment.

The experimental strategy underlying these conclusions combined several complementary approaches. Bioinformatic analysis of clinical data established the correlations between TIPE, DcR3-associated signaling, and M2 macrophage signatures in patient tumors. In vitro experiments using conditioned medium, the nutrient fluid in which cells have been grown, allowed the team to isolate the effects of tumor-derived factors on macrophage phenotype and to test the dependence of these effects on DcR3, HSPG2, heparan sulfate, and AKT1. In vivo models then provided the opportunity to observe the pathway operating within the complexity of a living system, where macrophages migrate, interact with multiple cell types, and respond to the full repertoire of tumor-derived signals. The convergence of evidence across these methods strengthens the case that the TIPE-DcR3-HSPG2-AKT1 axis is a genuine biological mechanism rather than a statistical coincidence.

The clinical implications of the work are twofold. First, the pathway offers potential diagnostic value. Because TIPE expression in tumor tissue tracks with the density and activity of M2 macrophages, measuring TIPE, or the M2 markers it induces, could help characterize the immune landscape of an individual patient’s tumor. In an era when immunotherapy success depends heavily on the state of the tumor microenvironment, such information could guide treatment decisions. Second, and perhaps more consequentially, each node in the identified pathway represents a candidate therapeutic target. Blocking the TIPE-driven upregulation of DcR3, interfering with the DcR3-HSPG2 interaction, disrupting heparan sulfate-dependent binding, or inhibiting AKT1 signaling in macrophages are all conceivable strategies for preventing the immune conversion that colorectal tumors rely upon. Existing drugs that target the broader PI3K-AKT pathway are already in clinical use for other cancers, which suggests that repurposing or refining such agents for macrophage-directed therapy in colorectal cancer is not an outlandish prospect.

Colorectal cancer remains a major global health burden, and while screening and surgical treatment have improved outcomes for many patients, advanced disease continues to claim a heavy toll. Immunotherapies that have transformed the treatment of some cancers have delivered more modest benefits in colorectal cancer overall, partly because many colorectal tumors are what oncologists describe as immunologically cold, lacking the inflamed, immune-cell-rich environment that checkpoint inhibitors require to work. Research that illuminates how tumors suppress and redirect immune cells therefore has value beyond the specific pathway involved. By showing that a single tumor-derived protein can orchestrate both the identity and the recruitment of macrophages through a defined molecular chain, this study adds a concrete mechanism to the growing understanding of how colorectal tumors build their protective microenvironment, and it hands researchers a map of specific, testable intervention points for future therapies.

The study, led by corresponding authors Yuhan Ye, Xingfeng Qiu, and Guohong Zhuang, with Shiying Zhang, Chunlin Shen, and Zeyang Lin as co-first authors, was conducted with ethical approval from Xiamen University and informed consent from all participants, and was supported by the National Natural Science Foundation of China along with provincial and municipal funding programs. As with any mechanistic study, the transition from laboratory findings to clinical application will require further validation, including the development of safe and effective ways to intervene in the pathway in patients. Nevertheless, by connecting TIPE, DcR3, HSPG2, heparan sulfate, AKT1, and CXCL8 into a single coherent signaling axis that governs macrophage polarization and recruitment, the research provides both a deeper understanding of colorectal cancer biology and a set of promising leads for the next generation of microenvironment-targeted treatments.

Subject of Research: TIPE-mediated DcR3 signaling driving M2 macrophage polarization in the colorectal cancer microenvironment

Article Title: The effect and mechanism of TIPE in promoting M2 polarization through DcR3 in the microenvironment of colorectal cancer

Article References: Zhang, S., Shen, C., Lin, Z., Zhu, Q., Feng, Y., Sun, L., Zhang, C., Zhang, H., Wang, L., Chen, S., Huang, J., Ye, Y., Qiu, X., & Zhuang, G. (2026). The effect and mechanism of TIPE in promoting M2 polarization through DcR3 in the microenvironment of colorectal cancer. Cancer Immunology, Immunotherapy, 75(10), Article 233. https://doi.org/10.1007/s00262-026-04531-8

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04531-8

Keywords: colorectal cancer, TIPE, DcR3, macrophage polarization, M2 macrophages, tumor microenvironment, HSPG2, AKT1 signaling, CXCL8, tumor immunology, immunosuppression, cancer immunotherapy

The research, led by Xiaoyan Li, Chunning Li and colleagues at the Cancer Hospital of China Medical University and Liaoning Cancer Hospital & Institute in Shenyang, began with an unbiased search for molecular features that distinguish tumors resistant to chemoimmunotherapy from those that shrink dramatically under treatment. Rather than examining genes in isolation, the team integrated two complementary high-resolution technologies. The first was proteomic profiling using liquid chromatography with tandem mass spectrometry, applied to clinical esophageal cancer specimens from eight patients, which allowed the researchers to catalogue thousands of proteins actually present inside the tumors. The second was single-cell RNA sequencing, performed on three esophageal tumors and one normal esophageal tissue sample, which provided a cell-by-cell map of gene expression across the entire tumor ecosystem, from malignant epithelial cells to stromal fibroblasts and infiltrating immune cells.

Converging evidence from these two approaches converged on a single molecule. CYP2S1, a member of the cytochrome P450 superfamily of enzymes best known for their roles in metabolizing fatty acids, drugs and other small molecules, stood out as significantly upregulated in tumors that had resisted chemoimmunotherapy. The single-cell data added a crucial layer of context: the enzyme was not produced uniformly throughout the tumor but was predominantly expressed by the malignant epithelial cells themselves. This tumor-intrinsic pattern of expression was important, because it suggested that the cancer cells were not merely passive victims of an unfavorable immune environment but were actively manufacturing a molecule associated with immune exclusion and treatment failure.

To move from correlation to biological plausibility, the investigators turned their attention to the tumor microenvironment, the complex ecosystem of immune and stromal cells that surrounds and infiltrates a tumor. Using immunohistochemistry, a technique that stains tissue sections to reveal the location and abundance of specific proteins, and multiplex immunofluorescence, which can visualize several protein markers simultaneously in the same tissue section, the team examined tumor samples at single-cell resolution. Their analyses revealed that tumors with high CYP2S1 expression contained markedly increased numbers of cells with the phenotypic characteristics of polymorphonuclear myeloid-derived suppressor cells, or PMN-MDSCs. These cells, which are related to neutrophils, are among the most potent immunosuppressive players in cancer biology. They accumulate in tumors under chronic inflammatory conditions and suppress the activity of cytotoxic T lymphocytes, the very cells that immune checkpoint inhibitors are designed to unleash against the cancer.

The clinical significance of this finding became apparent when the researchers examined the relationship between CYP2S1 protein levels and treatment response in a cohort of 46 evaluable patients who had undergone neoadjuvant chemoimmunotherapy. Response was assessed using the Mandard tumor regression grade, a pathological scoring system that pathologists use to quantify how much residual tumor remains after preoperative treatment, with lower grades indicating more complete tumor destruction. The results were striking: the CYP2S1 immunohistochemical score was positively associated with the tumor regression grade, meaning that patients whose tumors expressed more CYP2S1 tended to have less tumor regression and thus a poorer response to therapy. The statistical relationship was robust, with a linear regression analysis yielding an R-squared value of 0.271 and a P value of 0.0002, while a Spearman correlation coefficient of 0.528 with a P value below 0.001 confirmed the strength of the association.

With a firm clinical correlation established, the team turned to laboratory experiments to dissect the mechanism. Using short hairpin RNA and small interfering RNA techniques to reduce CYP2S1 expression in esophageal cancer cell lines, they observed that silencing the enzyme lowered intracellular levels of reactive oxygen species, the chemically reactive molecules containing oxygen that accumulate in stressed cells, and simultaneously reduced the expression of several chemokines known to attract myeloid cells. Conversely, when the researchers forced tumor cells to overproduce CYP2S1, reactive oxygen species accumulated and the cells secreted elevated amounts of two chemokines in particular: CXCL6 and CXCL8. Both of these signaling molecules belong to the CXC chemokine family and are well documented as chemoattractants for neutrophils and neutrophil-like suppressor cells, providing a plausible route by which tumor cell CYP2S1 could recruit PMN-MDSCs into the tumor bed.

To confirm that the chemokine induction was genuinely dependent on reactive oxygen species rather than some parallel effect of CYP2S1, the investigators performed a scavenging experiment using N-acetylcysteine, a well-established antioxidant that neutralizes intracellular reactive oxygen species. When cells overexpressing CYP2S1 were treated with N-acetylcysteine, the accumulation of reactive oxygen species was attenuated, the induction of CXCL6 and CXCL8 messenger RNA was reduced, and the secretion of CXCL8 protein declined. These results support a model in which CYP2S1 drives a reactive-oxygen-species-dependent signaling program that culminates in the production of myeloid-attracting chemokines. In this framework, the enzyme acts as a molecular switch inside malignant cells, converting metabolic and oxidative activity into an inflammatory signal that reshapes the immune composition of the surrounding tumor.

The broader implications of this work extend beyond esophageal squamous cell carcinoma. Cytochrome P450 enzymes have long interested cancer researchers because of their roles in drug metabolism and in the synthesis of signaling lipids, but CYP2S1 has remained comparatively understudied in the context of tumor immunology. By linking this enzyme to the reactive oxygen species, CXCL6 and CXCL8 axis and to the accumulation of immunosuppressive myeloid cells, the study adds a new node to the growing network of tumor-intrinsic mechanisms of immune evasion. It also offers a potential explanation for why some tumors with similar PD-L1 expression levels respond so differently to checkpoint inhibitors: the determinant of sensitivity may lie not in the checkpoint pathway itself but in whether the tumor has built a chemical wall of suppressive myeloid cells that antibodies cannot penetrate.

Translational possibilities follow naturally from these findings. If CYP2S1 expression in pretreatment biopsy samples proves predictive in larger cohorts, it could serve as a biomarker to identify patients unlikely to benefit from neoadjuvant chemoimmunotherapy, sparing them the toxicity of an ineffective regimen and directing them toward alternative strategies. More ambitiously, the CYP2S1–reactive oxygen species–CXCL6/CXCL8 pathway itself presents multiple candidate points of therapeutic intervention, from inhibiting the enzyme or its oxidative products to blocking the chemokine receptors that guide PMN-MDSCs into tumors. Such approaches would need careful validation, since reactive oxygen species play complex and sometimes protective roles in normal tissue biology, and myeloid cell biology differs substantially between mice and humans.

The study also carries methodological lessons for the field. By combining unbiased proteomics, single-cell transcriptomics, multiplex tissue imaging, patient-level pathological correlations and mechanistic cell biology within a single investigation, the researchers demonstrated how multi-omics integration can move a candidate biomarker from discovery to biological explanation in one continuous chain of evidence. The work adhered to the principles of the Declaration of Helsinki, received approval from the Ethics Committee of the Cancer Hospital of China Medical University, and all patients provided written informed consent. As chemoimmunotherapy becomes standard of care for more cancers and more patients, understanding why it fails will be as important as celebrating why it works. This study suggests that sometimes the answer lies in a quiet metabolic enzyme, humming away inside the tumor cell, quietly sending out the molecular invitations that summon the very cells that shield the cancer from destruction.

Subject of Research: CYP2S1-mediated recruitment of polymorphonuclear myeloid-derived suppressor cells and chemoimmunotherapy resistance in esophageal squamous cell carcinoma

Article Title: CYP2S1: a novel regulator of PMN-MDSC recruitment and immunotherapy resistance in esophageal squamous cell carcinoma

Article References: CYP2S1: a novel regulator of PMN-MDSC recruitment and immunotherapy resistance in esophageal squamous cell carcinoma. (n.d.). https://doi.org/10.1007/s00262-026-04556-z

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04556-z

Keywords: CYP2S1, esophageal squamous cell carcinoma, immunotherapy resistance, PMN-MDSC, tumor microenvironment, reactive oxygen species, CXCL6, CXCL8, chemoimmunotherapy, tumor regression grade, single-cell RNA sequencing, cancer immunology